ES2471915T3 - Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma - Google Patents
Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma Download PDFInfo
- Publication number
- ES2471915T3 ES2471915T3 ES11004496.3T ES11004496T ES2471915T3 ES 2471915 T3 ES2471915 T3 ES 2471915T3 ES 11004496 T ES11004496 T ES 11004496T ES 2471915 T3 ES2471915 T3 ES 2471915T3
- Authority
- ES
- Spain
- Prior art keywords
- amino acid
- residue
- sequence
- alkaline phosphatase
- signal peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/03—Phosphoric monoester hydrolases (3.1.3)
- C12Y301/03001—Alkaline phosphatase (3.1.3.1)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/025—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a parvovirus
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Physical Education & Sports Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Materials For Medical Uses (AREA)
- Enzymes And Modification Thereof (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cereal-Derived Products (AREA)
- Adornments (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US91758907P | 2007-05-11 | 2007-05-11 | |
| US917589P | 2007-05-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2471915T3 true ES2471915T3 (es) | 2014-06-27 |
Family
ID=40001639
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13002327T Active ES2619332T3 (es) | 2007-05-11 | 2008-05-12 | Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma |
| ES11004496.3T Active ES2471915T3 (es) | 2007-05-11 | 2008-05-12 | Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma |
| ES08757088T Active ES2380546T3 (es) | 2007-05-11 | 2008-05-12 | Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13002327T Active ES2619332T3 (es) | 2007-05-11 | 2008-05-12 | Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES08757088T Active ES2380546T3 (es) | 2007-05-11 | 2008-05-12 | Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20100297119A1 (OSRAM) |
| EP (3) | EP2158319B1 (OSRAM) |
| JP (1) | JP5732603B2 (OSRAM) |
| AT (1) | ATE536413T1 (OSRAM) |
| AU (1) | AU2008250945B2 (OSRAM) |
| BR (2) | BRPI0811198B8 (OSRAM) |
| CA (1) | CA2687001C (OSRAM) |
| CY (1) | CY2016005I2 (OSRAM) |
| DE (1) | DE202008018131U1 (OSRAM) |
| DK (3) | DK2368999T3 (OSRAM) |
| ES (3) | ES2619332T3 (OSRAM) |
| FR (1) | FR16C0007I2 (OSRAM) |
| HR (1) | HRP20140416T1 (OSRAM) |
| HU (2) | HUE031655T2 (OSRAM) |
| IL (1) | IL202057A0 (OSRAM) |
| LT (1) | LTC2368999I2 (OSRAM) |
| LU (1) | LU92976I2 (OSRAM) |
| ME (1) | ME01828B (OSRAM) |
| NL (1) | NL300798I2 (OSRAM) |
| NO (1) | NO2016002I2 (OSRAM) |
| PL (3) | PL2662448T3 (OSRAM) |
| PT (3) | PT2368999E (OSRAM) |
| RS (1) | RS53302B (OSRAM) |
| SI (2) | SI2662448T1 (OSRAM) |
| WO (1) | WO2008138131A1 (OSRAM) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3404102B1 (en) | 2004-04-21 | 2021-08-11 | Alexion Pharmaceuticals, Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
| US8784833B2 (en) * | 2006-06-27 | 2014-07-22 | Saint Louis University | Prenatal enzyme replacement therapy for hypophosphatasia |
| KR101580937B1 (ko) | 2007-06-01 | 2015-12-31 | 유니버시티 오브 매릴랜드, 발티모어 | 면역글로불린 불변영역 Ｆｃ 수용체 결합제 |
| WO2011113027A2 (en) | 2010-03-12 | 2011-09-15 | Synageva Biopharma Corp | Npp1 fusion proteins |
| CN103153344A (zh) | 2010-04-30 | 2013-06-12 | 阿莱克森国际制药有限公司 | 用于治疗基质矿化障碍的方法、组合物、和试剂盒 |
| DK2598533T3 (en) | 2010-07-28 | 2019-04-23 | Gliknik Inc | Fusion proteins of natural human protein fragments to create in an orderly fashion multimerized immunoglobulin FC compositions |
| US9266939B2 (en) | 2010-12-27 | 2016-02-23 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
| CA2852874A1 (en) * | 2011-10-19 | 2013-04-25 | Alexion Pharma Holding | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| JP2015527366A (ja) | 2012-08-20 | 2015-09-17 | グリックニック インコーポレイテッド | 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子 |
| CN106164262B (zh) * | 2014-01-24 | 2020-08-07 | 安-法玛公司 | 嵌合型碱性磷酸酶样蛋白 |
| US10822596B2 (en) | 2014-07-11 | 2020-11-03 | Alexion Pharmaceuticals, Inc. | Compositions and methods for treating craniosynostosis |
| EP3226891B1 (en) | 2014-12-05 | 2025-06-25 | Alexion Pharmaceuticals, Inc. | Treating seizure with recombinant alkaline phosphatase |
| JP6868561B2 (ja) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | アルカリホスファターゼ欠損を有する被験者を治療する方法 |
| FI3325011T6 (fi) | 2015-07-24 | 2023-05-11 | Ihmisen proteiinifragmenttien fuusioproteiineja järjestyksenmukaisesti multimerisoitujen, paremmin komplementtia sitovien immunoglobuliini-fc-koostumusten muodostamiseksi | |
| HK1257341A1 (zh) * | 2015-08-17 | 2019-10-18 | Alexion Pharmaceuticals, Inc. | 硷性磷酸酯的制造 |
| US11229686B2 (en) | 2015-09-28 | 2022-01-25 | Alexion Pharmaceuticals, Inc. | Reduced frequency dosage regimens for tissue non-specific alkaline phosphatase (TNSALP)-enzyme replacement therapy of hypophosphatasia |
| US11400140B2 (en) | 2015-10-30 | 2022-08-02 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
| EP3426286A4 (en) * | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | PROCESS FOR TREATING HYPOPHOSPHATASIA IN CHILDREN |
| WO2017173395A1 (en) * | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| WO2017171871A1 (en) * | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
| CN109152820A (zh) * | 2016-04-01 | 2019-01-04 | 阿雷克森制药公司 | 用碱性磷酸酶治疗肌肉无力 |
| US10988744B2 (en) | 2016-06-06 | 2021-04-27 | Alexion Pharmaceuticals, Inc. | Method of producing alkaline phosphatase |
| AU2017279538A1 (en) | 2016-06-07 | 2019-01-03 | Gliknik Inc. | Cysteine-optimized stradomers |
| ES2887573T3 (es) | 2016-06-27 | 2021-12-23 | Alexion Pharma Inc | Métodos para el tratamiento de la hipofosfatasia en niños y adolescentes |
| EP3500289B1 (en) | 2016-08-18 | 2024-10-09 | Alexion Pharmaceuticals, Inc. | Asfotase alfa for use in treating tracheobronchomalacia |
| JP7649624B2 (ja) * | 2016-11-30 | 2025-03-21 | パーデュー リサーチ ファウンデーション | 副甲状腺ホルモン受容体刺激を介する、骨折をターゲティングした骨再生 |
| WO2018107079A1 (en) | 2016-12-09 | 2018-06-14 | Gliknik Inc. | Manufacturing optimization of gl-2045, a multimerizing stradomer |
| IL266988B2 (en) | 2016-12-09 | 2024-11-01 | Gliknik Inc | Methods of treating inflammatory disorders with multivalent fc compounds |
| WO2018164995A1 (en) * | 2017-03-09 | 2018-09-13 | Alexion Pharmaceuticals, Inc . | Glycoprotein manufacturing process |
| CA3057502A1 (en) * | 2017-03-31 | 2018-10-04 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia (hpp) in adults and adolescents |
| JP7511469B2 (ja) | 2017-09-27 | 2024-07-05 | イノザイム ファーマ， インコーポレイテッド | 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。 |
| EP3737750B1 (en) | 2018-01-09 | 2024-06-05 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of neurodevelopmental disorders |
| JP7214962B2 (ja) * | 2018-01-17 | 2023-01-31 | 東ソー株式会社 | アルカリホスファターゼ高発現動物細胞 |
| EP3773686B1 (en) | 2018-03-20 | 2023-06-07 | Theriva Biologics, Inc. | Alkaline phosphatase agents for treatment of radiation disorders |
| ES3032290T3 (en) | 2018-03-20 | 2025-07-16 | Theriva Biologics Inc | Intestinal alkaline phosphatase formulations |
| US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
| CN110499285A (zh) * | 2018-05-17 | 2019-11-26 | 西安组织工程与再生医学研究所 | Alpl基因在制备预防和/或治疗低碱性磷酸酶症的产品中的应用 |
| WO2019232285A1 (en) | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| US12268733B2 (en) | 2018-08-10 | 2025-04-08 | Alexion Pharmaceuticals, Inc. | Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase |
| CN113993541A (zh) | 2019-05-06 | 2022-01-28 | 合成生物制品有限公司 | 基于碱性磷酸酶的肿瘤学治疗 |
| AU2020398898A1 (en) | 2019-12-09 | 2022-07-21 | Alexion Pharmaceuticals, Inc. | Alkaline phosphatase polypeptides and methods of use thereof |
| EP4084819A1 (en) | 2020-01-03 | 2022-11-09 | The United States of America, as represented by the Secretary, Department of Health and Human Services | Tnap locally administered for promoting periodontal health |
| CA3190513A1 (en) * | 2020-09-03 | 2022-03-10 | Jeffrey S. Bartlett | Soluble alkaline phosphatase constructs and expression vectors including a polynucleotide encoding for soluble alkaline phosphatase constructs |
| KR102571967B1 (ko) * | 2021-01-21 | 2023-08-30 | 주식회사 마라나노텍코리아 | Alp 측정용 바이오 센서 |
| CN117042791A (zh) | 2021-02-12 | 2023-11-10 | 阿雷克森制药公司 | 碱性磷酸酶多肽及其使用方法 |
| WO2024050464A2 (en) * | 2022-08-31 | 2024-03-07 | University Of Utah Research Foundation | Gja1-20k compositions and methods for mitigating ischemia-reperfusion injury |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7008A (en) * | 1850-01-08 | Improvement in alloys for points of lightning-rods | ||
| AU687829B2 (en) | 1993-06-24 | 1998-03-05 | Advec, Inc. | Adenovirus vectors for gene therapy |
| HU223733B1 (hu) | 1993-10-25 | 2004-12-28 | Canji, Inc. | Rekombináns adenovírus vektor és eljárás alkalmazására |
| US7252989B1 (en) | 1994-04-04 | 2007-08-07 | Board Of Regents, The University Of Texas System | Adenovirus supervector system |
| ES2284545T3 (es) | 1999-11-16 | 2007-11-16 | Genzyme Corporation | Vectores y transgenes con elementos reguladores para la administracion de genes del higado. |
| US6808905B2 (en) | 2001-05-14 | 2004-10-26 | Cell Genesys, Inc. | Lentiviral vectors encoding clotting factors for gene therapy |
| CA2433479A1 (en) | 2002-07-22 | 2004-01-22 | F. Hoffmann-La Roche Ag | Conjugate of a tissue non-specific alkaline phosphatase and dextran, process for its production and use thereof |
| EP3404102B1 (en) | 2004-04-21 | 2021-08-11 | Alexion Pharmaceuticals, Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| US20070081984A1 (en) | 2005-10-11 | 2007-04-12 | Shunji Tomatsu | Compositions and methods for treating hypophosphatasia |
| WO2006002203A2 (en) | 2004-06-23 | 2006-01-05 | Genzyme Corporation | Methods and compositions for the treatment of polycystic diseases |
| WO2006039480A2 (en) * | 2004-09-29 | 2006-04-13 | The Burnham Institute For Medical Research | Tissue non-specific alkaline phosphate (tnap): a therapeutic target for arterial calcification |
| BRPI0515819A (pt) | 2004-12-01 | 2008-08-05 | Genzyme Corp | métodos para o fornecimento direcionado de material genético ao fìgado |
-
2008
- 2008-05-12 JP JP2010507770A patent/JP5732603B2/ja active Active
- 2008-05-12 ME MEP-2014-48A patent/ME01828B/me unknown
- 2008-05-12 EP EP08757088A patent/EP2158319B1/en active Active
- 2008-05-12 AU AU2008250945A patent/AU2008250945B2/en active Active
- 2008-05-12 PT PT110044963T patent/PT2368999E/pt unknown
- 2008-05-12 DE DE202008018131U patent/DE202008018131U1/de not_active Expired - Lifetime
- 2008-05-12 EP EP11004496.3A patent/EP2368999B1/en active Active
- 2008-05-12 CA CA2687001A patent/CA2687001C/en active Active
- 2008-05-12 PL PL13002327T patent/PL2662448T3/pl unknown
- 2008-05-12 SI SI200831780A patent/SI2662448T1/sl unknown
- 2008-05-12 AT AT08757088T patent/ATE536413T1/de active
- 2008-05-12 PL PL11004496T patent/PL2368999T3/pl unknown
- 2008-05-12 RS RS20140237A patent/RS53302B/sr unknown
- 2008-05-12 EP EP13002327.8A patent/EP2662448B1/en active Active
- 2008-05-12 DK DK11004496.3T patent/DK2368999T3/da active
- 2008-05-12 DK DK08757088.3T patent/DK2158319T3/da active
- 2008-05-12 WO PCT/CA2008/000923 patent/WO2008138131A1/en not_active Ceased
- 2008-05-12 DK DK13002327.8T patent/DK2662448T3/en active
- 2008-05-12 ES ES13002327T patent/ES2619332T3/es active Active
- 2008-05-12 PT PT130023278T patent/PT2662448T/pt unknown
- 2008-05-12 HU HUE13002327A patent/HUE031655T2/hu unknown
- 2008-05-12 BR BRPI0811198A patent/BRPI0811198B8/pt active IP Right Grant
- 2008-05-12 PL PL08757088T patent/PL2158319T4/pl unknown
- 2008-05-12 US US12/599,679 patent/US20100297119A1/en not_active Abandoned
- 2008-05-12 BR BR122019000505-2A patent/BR122019000505B1/pt active Search and Examination
- 2008-05-12 ES ES11004496.3T patent/ES2471915T3/es active Active
- 2008-05-12 SI SI200831200T patent/SI2368999T1/sl unknown
- 2008-05-12 ES ES08757088T patent/ES2380546T3/es active Active
- 2008-05-12 PT PT08757088T patent/PT2158319E/pt unknown
-
2009
- 2009-11-11 IL IL202057A patent/IL202057A0/en unknown
-
2014
- 2014-05-08 HR HRP20140416AT patent/HRP20140416T1/hr unknown
-
2016
- 2016-01-15 HU HUS1600005C patent/HUS1600005I1/hu unknown
- 2016-01-28 LT LTPA2016004C patent/LTC2368999I2/lt unknown
- 2016-02-02 NO NO2016002C patent/NO2016002I2/no not_active IP Right Cessation
- 2016-02-10 LU LU92976C patent/LU92976I2/xx unknown
- 2016-02-19 FR FR16C0007C patent/FR16C0007I2/fr active Active
- 2016-02-23 CY CY2016005C patent/CY2016005I2/el unknown
- 2016-02-26 NL NL300798C patent/NL300798I2/nl unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2471915T3 (es) | Fosfatasa alcalina dirigida al hueso, kits y métodos de uso de la misma | |
| Millán et al. | Alkaline phosphatase and hypophosphatasia | |
| Millán et al. | Enzyme replacement therapy for murine hypophosphatasia | |
| ES3038086T3 (en) | Treating seizure with recombinant alkaline phosphatase | |
| ES2401805T3 (es) | Antagonistas de activina-ActRlla y usos para promover el crecimiento óseo | |
| US9988620B2 (en) | Methods, compositions, and kits for the treatment of matrix mineralization disorders | |
| JP4874954B2 (ja) | 骨送達複合体ならびにタンパク質に骨を標的化させるためのその使用方法 | |
| JP2023011741A (ja) | アクチビン－ＡｃｔＲＩＩアンタゴニスト並びに骨障害及び他の障害の治療に対する使用 | |
| JP2022160503A (ja) | キメラアルカリホスファターゼ様タンパク質 | |
| ES2234032T3 (es) | Terapia para la deficiencia de alfa-galactosidasa a. | |
| BRPI0806861A2 (pt) | Antagonistas de ativina-actriia e usos para tratar ou prevenir câncer de mama | |
| ES2796743T3 (es) | Un polipéptido de receptor de factor de crecimiento de fibroblastos 3 (FGR3) soluble para su uso en la prevención o tratamiento de trastornos de retraso del crecimiento esquelético | |
| JP2015536658A (ja) | 標的化イズロン酸−２−スルファターゼ化合物 | |
| HK1141047B (en) | Bone targeted alkaline phosphatase, kits and methods of use thereof | |
| HK1162589B (en) | Bone targeted alkaline phosphatase, kits and methods of use thereof | |
| HK1191372B (en) | Bone targeted alkaline phosphatase, kits and methods of use thereof | |
| AU2013203875A1 (en) | Bone Targeted Alkaline Phosphatase, Kits and Methods of Use Thereof |